

FEB. 6. 2009 1:53PM  
TO: USPTO

ZILKA-KOTAB, PC

NO. 1744 P. 1

# NOVARTIS PHARMACEUTICALS CORPORATION

RECEIVED  
CENTRAL FAX CENTER

FEB 06 2009

150 INDUSTRIAL ROAD  
SAN CARLOS, CA 94070

TELEPHONE (650) 622-1599  
FAX (650) 622-1699

## FAX COVER SHEET

Date: February 6, 2009	Phone Number	Fax Number
To: Examiner Carter		(571) 273-8300
From: Michael J. Mazza		

Docket No.: 53311-US-CNT/0190.00

App. No: 10/751,342

Total Number of Pages Being Transmitted, Including Cover Sheet: 18

### Message:

Please deliver to Examiner Carter.

Thank you,  
/Michael J. Mazza/  
Michael J. Mazza

☐ Original to follow Via Regular Mail ☒ Original will Not be Sent ☐ Original will follow Via Overnight Courler

\*\*\*\*\*  
The information contained in this facsimile message is attorney privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone (if long distance, please call collect) and return the original message to us at the above address via the U.S. Postal Service. Thank you.  
\*\*\*\*\*

IF YOU DO NOT RECEIVE ALL PAGES OR IF YOU ENCOUNTER  
ANY OTHER DIFFICULTY, PLEASE PHONE April  
AT (408) 971-2573 AT YOUR EARLIEST CONVENIENCE

February 6, 2009

FEB. 6. 2009 1:53PM

ZILKA-KOTAB, PC

RECEIVED  
CENTRAL FAX CENTER

NO. 1744 P. 2

FEB 06 2009

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jeffrey G. Weers

Application No.: 10/751,342

Filed: 12/31/2003

For: AEROSOLIZABLE PHARMACEUTICAL  
FORMULATION FOR FUNGAL INFECTION THERAPY

) Attorney Docket No.: 53311-US-CNT/0190.00

) Examiner: Carter, Kendra D.

) Group Art Unit: 1617

) Date: February 6, 2009

CERTIFICATE OF FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents at fax number (571) 273-8300 on February 6, 2009.

Signed:

  
April Skovmand

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.



Applicant(s) hereby petition for a 1 month extension of time to respond to the outstanding Office Action.



Applicant(s) believe that no additional Extension of Time is required; however, if it is determined that such an extension is required, Applicant(s) hereby petition that such an extension be granted and authorize the Commissioner to charge the required fees for an Extension of Time under 37 CFR 1.136 to Deposit Account No. 19-0134.



If the required fees are missing or any additional fees are required to facilitate filing the enclosed response, please charge such fees or credit any overpayment to Deposit Account No. 19-0134 (Order No. 5331-US-CNT). A copy of this sheet is enclosed for billing purposes.

Respectfully submitted,  
Novartis Pharmaceuticals Corporation,

/Michael J. Mazza/

Michael J. Mazza  
Registration No. 30,775

USSC - Novartis Pharmaceuticals Corporation  
150 Industrial Road  
San Carlos, CA 94070

Phone: 650 622 1599  
Fax: 650 622 1699  
Cell: 650 283 6790

FEB. 6. 2009 1:53PM

ZILKA-KOTAB, PC

RECEIVED  
CENTRAL FAX CENTER

NO. 1744 P. 3

FEB 06 2009



COPY  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jeffrey G. Weers

Application No.: 10/751,342

Filed: 12/31/2003

For: AEROSOLIZABLE PHARMACEUTICAL  
FORMULATION FOR FUNGAL INFECTION THERAPY

) Attorney Docket No.: 53311-US-CNT/0190.00

) Examiner: Carter, Kendra D.

) Group Art Unit: 1617

) Date: February 6, 2009

CERTIFICATE OF FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents at fax number (571) 273-8300 on February 6, 2009.

Signed: April Skovmand  
April Skovmand

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☒ Applicant(s) hereby petition for a 1 month extension of time to respond to the outstanding Office Action.
- ☒ Applicant(s) believe that no additional Extension of Time is required; however, if it is determined that such an extension is required, Applicant(s) hereby petition that such an extension be granted and authorize the Commissioner to charge the required fees for an Extension of Time under 37 CFR 1.136 to Deposit Account No. 19-0134.
- ☒ If the required fees are missing or any additional fees are required to facilitate filing the enclosed response, please charge such fees or credit any overpayment to Deposit Account No. 19-0134 (Order No. 5331-US-CNT). A copy of this sheet is enclosed for billing purposes.

Respectfully submitted,  
Novartis Pharmaceuticals Corporation,

/Michael J. Mazza/

Michael J. Mazza  
Registration No. 30,775

USSC - Novartis Pharmaceuticals Corporation  
150 Industrial Road  
San Carlos, CA 94070

Phone: 650 622 1599  
Fax: 650 622 1699  
Cell: 650 283 6790